Johnson & Johnson $JNJ Shares Bought by Farmers Trust Co.

Farmers Trust Co. grew its stake in Johnson & Johnson (NYSE:JNJ) by 12.5% during the fourth quarter, HoldingsChannel.com reports. The firm owned 56,076 shares of the company’s stock after purchasing an additional 6,233 shares during the period. Johnson & Johnson makes up approximately 1.9% of Farmers Trust Co.’s holdings, making the stock its 9th biggest holding. Farmers Trust Co.’s holdings in Johnson & Johnson were worth $11,605,000 as of its most recent filing with the SEC.

Several other large investors have also modified their holdings of the stock. Avior Wealth Management LLC grew its stake in Johnson & Johnson by 1.1% in the fourth quarter. Avior Wealth Management LLC now owns 31,519 shares of the company’s stock worth $6,523,000 after purchasing an additional 343 shares in the last quarter. First Citizens Financial Corp raised its stake in Johnson & Johnson by 1.0% during the fourth quarter. First Citizens Financial Corp now owns 7,253 shares of the company’s stock valued at $1,501,000 after buying an additional 72 shares in the last quarter. JBR Co Financial Management Inc acquired a new stake in Johnson & Johnson during the fourth quarter valued at approximately $222,000. Hiley Hunt Wealth Management lifted its holdings in Johnson & Johnson by 12.4% during the 4th quarter. Hiley Hunt Wealth Management now owns 1,857 shares of the company’s stock worth $384,000 after buying an additional 205 shares during the last quarter. Finally, Neville Rodie & Shaw Inc. grew its position in shares of Johnson & Johnson by 2.2% in the 4th quarter. Neville Rodie & Shaw Inc. now owns 166,185 shares of the company’s stock worth $34,391,000 after acquiring an additional 3,503 shares in the last quarter. Institutional investors own 69.55% of the company’s stock.

Insider Transactions at Johnson & Johnson

In other Johnson & Johnson news, EVP Timothy Schmid sold 1,322 shares of the firm’s stock in a transaction that occurred on Friday, February 20th. The shares were sold at an average price of $245.66, for a total value of $324,762.52. Following the sale, the executive vice president owned 25,447 shares in the company, valued at approximately $6,251,310.02. This trade represents a 4.94% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, EVP Vanessa Broadhurst sold 6,197 shares of Johnson & Johnson stock in a transaction that occurred on Tuesday, February 17th. The shares were sold at an average price of $243.39, for a total value of $1,508,287.83. Following the sale, the executive vice president directly owned 23,003 shares in the company, valued at approximately $5,598,700.17. This trade represents a 21.22% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last ninety days, insiders sold 30,142 shares of company stock worth $7,360,528. Corporate insiders own 0.16% of the company’s stock.

Johnson & Johnson Trading Down 0.8%

NYSE:JNJ opened at $235.64 on Friday. Johnson & Johnson has a 12-month low of $141.50 and a 12-month high of $251.71. The firm has a market capitalization of $567.57 billion, a P/E ratio of 21.32, a P/E/G ratio of 2.32 and a beta of 0.34. The company has a debt-to-equity ratio of 0.48, a current ratio of 1.03 and a quick ratio of 0.77. The business has a 50 day simple moving average of $235.21 and a 200 day simple moving average of $208.59.

Johnson & Johnson (NYSE:JNJ) last issued its earnings results on Saturday, January 31st. The company reported $2.46 earnings per share for the quarter. Johnson & Johnson had a return on equity of 33.04% and a net margin of 28.46%.The firm had revenue of $24.28 billion for the quarter. Equities research analysts predict that Johnson & Johnson will post 10.58 EPS for the current year.

Johnson & Johnson Dividend Announcement

The company also recently declared a quarterly dividend, which was paid on Tuesday, March 10th. Stockholders of record on Tuesday, February 24th were given a dividend of $1.30 per share. The ex-dividend date was Tuesday, February 24th. This represents a $5.20 annualized dividend and a dividend yield of 2.2%. Johnson & Johnson’s dividend payout ratio is currently 47.06%.

Analyst Ratings Changes

A number of brokerages have recently weighed in on JNJ. Argus boosted their price target on Johnson & Johnson from $210.00 to $240.00 in a report on Friday, January 23rd. Weiss Ratings reaffirmed a “buy (b)” rating on shares of Johnson & Johnson in a report on Wednesday, January 28th. Loop Capital set a $220.00 target price on shares of Johnson & Johnson in a research note on Tuesday, January 27th. Daiwa Securities Group increased their target price on shares of Johnson & Johnson from $203.00 to $237.00 and gave the stock an “outperform” rating in a report on Thursday, January 29th. Finally, Royal Bank Of Canada raised their price target on shares of Johnson & Johnson from $240.00 to $255.00 and gave the stock an “outperform” rating in a research report on Tuesday, February 3rd. One research analyst has rated the stock with a Strong Buy rating, seventeen have given a Buy rating and nine have given a Hold rating to the company. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $236.91.

Key Johnson & Johnson News

Here are the key news stories impacting Johnson & Johnson this week:

• Positive Sentiment: FDA approves Icotyde — expands J&J’s immunology/new drug portfolio with the first oral IL‑23 receptor antagonist, creating multi‑billion dollar revenue potential and unlocking milestone/royalty pathways with partners. Johnson & Johnson announces U.S. FDA approved Icotyde
• Positive Sentiment: Bullish analyst support — HSBC raised its price target to $280 (Buy) and Morgan Stanley reiterated a Buy with a $262 target, reinforcing upside expectations for J&J’s immunology growth. These firm-level views support longer‑term upside. HSBC Raises Johnson & Johnson Price Target TipRanks / Morgan Stanley note
• Neutral Sentiment: Clinical collaboration for prostate cancer — J&J signed a clinical‑supply agreement with GI Innovation to test a combo therapy in mCRPC (Phase 1b). Early‑stage, potentially value‑creating but long horizon. GI Innovation Announces First Clinical Supply Agreement
• Neutral Sentiment: Barclays raised its price target to $234 but kept an Equal Weight rating — a modest constructive signal, though the rating implies limited near‑term upside from current levels. Barclays Sees Continued Strength in J&J Pharma Business
• Neutral Sentiment: Partner (Protagonist) implications — Protagonist Therapeutics shares have rallied on Icotyde approval news because of milestone/royalty potential; that upside can translate into contingent payments to J&J’s partners but is secondary to J&J’s own sales path. Protagonist Therapeutics Stock Rallies Nearly 7%
• Negative Sentiment: Profit‑taking and macro skepticism — after a large run‑up in JNJ shares, investors appear to be trimming positions; market‑level concerns (stagflation commentary from influential voices) and cautious broker ratings (Equal Weight from Barclays) likely pressured the stock despite the positive product and analyst news. Jim Cramer on Johnson & Johnson

Johnson & Johnson Company Profile

Johnson & Johnson is a multinational healthcare company headquartered in New Brunswick, New Jersey, that develops, manufactures and markets a broad range of products across pharmaceuticals, medical devices and previously consumer health. Founded in 1886 by the Johnson family, the company has grown into a global healthcare organization with operations and sales in many countries around the world.

The company’s pharmaceuticals business, organized largely under its Janssen research and development organization, focuses on prescription medicines across therapeutic areas such as immunology, infectious disease, oncology and neuroscience.